Tags

Type your tag names separated by a space and hit enter

Medication adherence/persistence among patients with active multiple sclerosis in Finland.
Acta Neurol Scand. 2020 Jun 19 [Online ahead of print]AN

Abstract

OBJECTIVES

To explore adherence, persistence, and treatment patterns in patients with multiple sclerosis (MS) in Finland treated with disease-modifying therapies (DMTs) for active MS in 2005-2018.

MATERIALS AND METHODS

The study cohort was identified using the Drug Prescription Register of Social Insurance Institute, Finland. All patients had at least one prescription of glatiramer acetate (GA), beta-interferons, teriflunomide, or delayed-release dimethyl fumarate (DMF). Adherence was calculated using proportion of days covered (PDC) (cutoff ≥0.8). Time to non-persistence was calculated by the number of days on index DMT treatment before the first treatment gap (≥90 days) or switch and analyzed with time-to-event methodology.

RESULTS

The cohort included 7474 MS patients (72.2% female; mean age 38.9 years). Treatment switches were steady over 2005-2012, peaked in 2015. PDC means (standard deviations) were GA, 0.87 (0.17); beta-interferons, 0.88 (0.15); DMF, 0.89 (0.14); teriflunomide, 0.93 (0.10). Adherence frequencies were GA, 78.4%; beta-interferons, 81.3%; DMF, 86.9%; teriflunomide, 91.7%. Logistic regression showed that age group, DMT and the starting year, sex, and hospital district independently affected adherence. Patients receiving teriflunomide and DMF, males, and older patients were more likely to persist on treatment. There was no difference in persistence between patients prescribed teriflunomide and DMF, or between GA and beta-interferons.

CONCLUSIONS

Oral DMTs had greater adherence and persistence than injectable DMTs.

Authors+Show Affiliations

Biogen Finland Oy, Espoo, Finland.Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland.Tampere University Hospital, Tampere, Finland. Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland.Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.4Pharma, Helsinki, Finland.Biogen Finland Oy, Espoo, Finland. Biogen, Stockholm, Sweden.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32559310

Citation

Lahdenperä, Sanni, et al. "Medication Adherence/persistence Among Patients With Active Multiple Sclerosis in Finland." Acta Neurologica Scandinavica, 2020.
Lahdenperä S, Soilu-Hänninen M, Kuusisto HM, et al. Medication adherence/persistence among patients with active multiple sclerosis in Finland. Acta Neurol Scand. 2020.
Lahdenperä, S., Soilu-Hänninen, M., Kuusisto, H. M., Atula, S., Junnila, J., & Berglund, A. (2020). Medication adherence/persistence among patients with active multiple sclerosis in Finland. Acta Neurologica Scandinavica. https://doi.org/10.1111/ane.13301
Lahdenperä S, et al. Medication Adherence/persistence Among Patients With Active Multiple Sclerosis in Finland. Acta Neurol Scand. 2020 Jun 19; PubMed PMID: 32559310.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Medication adherence/persistence among patients with active multiple sclerosis in Finland. AU - Lahdenperä,Sanni, AU - Soilu-Hänninen,Merja, AU - Kuusisto,Hanna-Maija, AU - Atula,Sari, AU - Junnila,Jouni, AU - Berglund,Anders, Y1 - 2020/06/19/ PY - 2020/02/25/received PY - 2020/06/10/revised PY - 2020/06/15/accepted PY - 2020/6/20/pubmed PY - 2020/6/20/medline PY - 2020/6/20/entrez KW - adherence KW - medication KW - medication non-adherence KW - medication persistence KW - multiple sclerosis KW - relapsing-remitting JF - Acta neurologica Scandinavica JO - Acta Neurol. Scand. N2 - OBJECTIVES: To explore adherence, persistence, and treatment patterns in patients with multiple sclerosis (MS) in Finland treated with disease-modifying therapies (DMTs) for active MS in 2005-2018. MATERIALS AND METHODS: The study cohort was identified using the Drug Prescription Register of Social Insurance Institute, Finland. All patients had at least one prescription of glatiramer acetate (GA), beta-interferons, teriflunomide, or delayed-release dimethyl fumarate (DMF). Adherence was calculated using proportion of days covered (PDC) (cutoff ≥0.8). Time to non-persistence was calculated by the number of days on index DMT treatment before the first treatment gap (≥90 days) or switch and analyzed with time-to-event methodology. RESULTS: The cohort included 7474 MS patients (72.2% female; mean age 38.9 years). Treatment switches were steady over 2005-2012, peaked in 2015. PDC means (standard deviations) were GA, 0.87 (0.17); beta-interferons, 0.88 (0.15); DMF, 0.89 (0.14); teriflunomide, 0.93 (0.10). Adherence frequencies were GA, 78.4%; beta-interferons, 81.3%; DMF, 86.9%; teriflunomide, 91.7%. Logistic regression showed that age group, DMT and the starting year, sex, and hospital district independently affected adherence. Patients receiving teriflunomide and DMF, males, and older patients were more likely to persist on treatment. There was no difference in persistence between patients prescribed teriflunomide and DMF, or between GA and beta-interferons. CONCLUSIONS: Oral DMTs had greater adherence and persistence than injectable DMTs. SN - 1600-0404 UR - https://www.unboundmedicine.com/medline/citation/32559310/Medication_adherence/persistence_among_patients_with_active_multiple_sclerosis_in_Finland L2 - https://doi.org/10.1111/ane.13301 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.